Log in to save to my catalogue
Log in to save to my catalogue

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

| Ask | Become a Library member

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2117387079

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

About this item

Publication information

Publisher

New York: Nature Publishing Group US

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients
1
,
2
. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be more effective than nivolumab monotherapy
3
. Preclinical work suggests that neo...

Alternative Titles

Full title

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2117387079

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2117387079

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-018-0198-0

How to access this item

Log in as a Library member

View record in Gale

About resource

View in old catalogue

Connecting people and collections